Compositions having pesticidal activity and methods for their use are provided. Compositions include isolated and recombinant polypeptides having pesticidal activity, recombinant and synthetic nucleic acid molecules encoding the polypeptides, DNA constructs and vectors comprising the nucleic acid molecules, host cells comprising the vectors, and antibodies to the polypeptides. Polynucleotide sequences encoding the polypeptides can be used in DNA constructs or expression cassettes for transformation and expression in organisms of interest. The compositions and methods provided are useful for producing organisms with enhanced pest resistance or tolerance. Transgenic plants and seeds comprising a nucleotide sequence that encodes a pesticidal protein of the invention are also provided. Such plants are resistant to insects and other pests. Methods are provided for producing the various polypeptides disclosed herein, and for using those polypeptides for controlling or killing a pest. Methods and kits for detecting polypeptides of the invention in a sample are also included.

A transport protein coding gene, and a method for efficient production of L-tryptophan by a strain containing the gene. Specifically, by heterologous expression of ywkB gene from Bacillus subtilis on the genome of Escherichia coli, L-tryptophan production efficiency of the strain can be improved. Performing shake flask fermentation with the strain can accumulate 15.2 g/L of L-tryptophan within 24 h, which is 35% higher than a control strain.

The present invention provides a method for producing a fermentation product by culturing recombinant exosporium-producing Bacillus cells that express a fusion protein of interest on the exosporium in a medium containing sources of carbon and nitrogen in a total concentration of at least 20 g/L, resulting in a fermentation broth containing a high titer of the recombinant Bacillus spores.

The present disclosure is in the technical field of synthetic biology and metabolic engineering. The disclosure provides engineered viable bacteria. In particular, the disclosure provides viable bacteria with reduced cell wall biosynthesis additionally modified for production of glycosylated product. The disclosure further provides methods of generating viable bacteria and uses thereof. Furthermore, the disclosure in the technical field of fermentation of metabolically engineered microorganisms producing glycosylated product.

The present disclosure is generally related to compositions and methods for constructing and obtaining Bacillus sp. host cells (strains) having enhanced protein production phenotypes. Certain embodiments of the disclosure are therefore related to genetically modified Bacillus sp. cells derived (obtained) from parental Bacillus sp. cells (e.g., such as parental Bacillus cells expressing/producing a protein of interest). Thus, certain embodiments are directed to modified Bacillus sp. cells expressing/producing an endogenous protein of interest, or a heterologous protein of interest, wherein the modified Bacillus sp. cell comprises a genetic modification of a yitMOP operon, a combined genetic modification of a yitMOP operon and a sdpABC operon, a genetic modification of a yitM gene and the like, wherein the modified Bacillus sp. cells produce an increased amount of the POI relative the parental cells from which they were derived (i.e., when grown/cultivated/fermented under identical conditions).

The present disclosure is generally related to compositions and methods for constructing and obtaining Bacillus sp. host cells (strains) having enhanced protein production phenotypes. Certain embodiments of the disclosure are therefore related to genetically modified Bacillus sp. cells derived (obtained) from parental Bacillus sp. cells (e.g., such as parental Bacillus cells expressing/producing a protein of interest). Thus, certain embodiments are directed to modified Bacillus sp. cells expressing/producing an endogenous protein of interest, or a heterologous protein of interest, wherein the modified Bacillus sp. cell comprises a genetic modification of a yitMOP operon, a combined genetic modification of a yitMOP operon and a sdpABC operon, a genetic modification of a yitM gene and the like, wherein the modified Bacillus sp. cells produce an increased amount of the POI relative the parental cells from which they were derived (i.e., when grown/cultivated/fermented under identical conditions).

Methods and compositions are provided for modifying the genome of Bacillus sp. cells without the use of a selectable marker and without the use of a guided Cas endonuclease. The disclosure includes methods for integrating donor DNA sequences into the genome of a Bacillus sp. cell without the use of a selectable marker and without the use of Cas endonucleases into said genome, as well as methods for deleting genes of interest and/or providing point mutations into the genome of Bacillus sp. cells.

The present invention relates to a chimeric antigen receptor having a ligand specifically targeting an anthrax toxin receptor (ANTXR), and, more specifically, to: a nucleic acid encoding a chimeric antigen receptor comprising ligand PA63 specifically binding to anthrax toxin receptor 1 (ANTXR1) or anthrax toxin receptor 2 (ANTXR2); a vector comprising the nucleic acid encoding a chimeric antigen receptor; and a recombinant cell comprising the vector; a pharmaceutical composition for preventing or treating solid cancer, comprising the recombinant cell; and a treatment method. Solid cancer can be treated using an anti-ANTXR chimeric antigen receptor (CAR)-T cell, according to the present invention, and since the chimeric antigen receptor (CAR)-T cell is administered to patients with solid cancer for whom anti-cancer drug administration is not effective, especially patients with pancreatic cancer, drug administration is limited, and customized solid cancer prevention or treatment, which are efficient and safe, is possible.

The present invention relates to a chimeric antigen receptor having a ligand specifically targeting an anthrax toxin receptor (ANTXR), and, more specifically, to: a nucleic acid encoding a chimeric antigen receptor comprising ligand PA63 specifically binding to anthrax toxin receptor 1 (ANTXR1) or anthrax toxin receptor 2 (ANTXR2); a vector comprising the nucleic acid encoding a chimeric antigen receptor; and a recombinant cell comprising the vector; a pharmaceutical composition for preventing or treating solid cancer, comprising the recombinant cell; and a treatment method. Solid cancer can be treated using an anti-ANTXR chimeric antigen receptor (CAR)-T cell, according to the present invention, and since the chimeric antigen receptor (CAR)-T cell is administered to patients with solid cancer for whom anti-cancer drug administration is not effective, especially patients with pancreatic cancer, drug administration is limited, and customized solid cancer prevention or treatment, which are efficient and safe, is possible.

The present disclosure features the chimeric gas vesicle (CGV) and its expression in E. coli. The chimeric gas vesicle comprises two or more gas vesicle rib proteins. The heterologous peptides, 6-AA to 56-AA long, can be inserted into one recombinant rib protein in frame. The resulting CGV carrying the heterologous peptide can be used in many applications.